| LRRK2 activation in idiopathic Parkinson¢s disease R Di Maio, EK Hoffman, EM Rocha, MT Keeney, LH Sanders, ... Science translational medicine 10 (451), eaar5429, 2018 | 433 | 2018 |
| Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice L Chen, Y Ding, B Cagniard, AD Van Laar, A Mortimer, W Chi, ... Journal of Neuroscience 28 (2), 425-433, 2008 | 270 | 2008 |
| Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells R Tehranian, SE Montoya, AD Van Laar, TG Hastings, RG Perez Journal of neurochemistry 99 (4), 1188-1196, 2006 | 134 | 2006 |
| Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease CW Christine, KS Bankiewicz, AD Van Laar, RM Richardson, B Ravina, ... Annals of neurology 85 (5), 704-714, 2019 | 115 | 2019 |
| Erythropoietin protects against 6‐hydroxydopamine‐induced dopaminergic cell death AP Signore, Z Weng, T Hastings, AD Van Laar, Q Liang, YJ Lee, J Chen Journal of neurochemistry 96 (2), 428-443, 2006 | 106 | 2006 |
| GDNF and Parkinson¢s disease: where next? A summary from a recent workshop RA Barker, A Björklund, DM Gash, A Whone, A Van Laar, JH Kordower, ... Journal of Parkinson's disease 10 (3), 875-891, 2020 | 95 | 2020 |
| Phenotypic variability in three families with valosin‐containing protein mutation S Spina, AD Van Laar, JR Murrell, RL Hamilton, JK Kofler, F Epperson, ... European journal of neurology 20 (2), 251-258, 2013 | 81 | 2013 |
| Outcomes of interventional-MRI versus microelectrode recording-guided subthalamic deep brain stimulation PS Lee, GM Weiner, D Corson, J Kappel, YF Chang, VR Suski, ... Frontiers in neurology 9, 241, 2018 | 57 | 2018 |
| Long-term RNAi knockdown of á-synuclein in the adult rat substantia nigra without neurodegeneration A Zharikov, Q Bai, BR De Miranda, A Van Laar, JT Greenamyre, ... Neurobiology of disease 125, 146-153, 2019 | 44 | 2019 |
| Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial CW Christine, RM Richardson, AD Van Laar, ME Thompson, EM Fine, ... Neurology 98 (1), e40-e50, 2022 | 34 | 2022 |
| Aromatic L‐amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's disease JG Nutt, C Curtze, A Hiller, S Anderson, PS Larson, AD Van Laar, ... Movement Disorders 35 (5), 851-858, 2020 | 34 | 2020 |
| Frontotemporal dementia associated with a Valosin‐Containing Protein mutation: report of three families S Spina, AD Van Laar, JR Murrell, G de Courten‐Myers, RL Hamilton, ... The FASEB Journal 22, 58.4-58.4, 2008 | 29 | 2008 |
| Gene therapy for Parkinson¢s disease: contemporary practice and emerging concepts A Merola, A Van Laar, R Lonser, K Bankiewicz Expert review of neurotherapeutics 20 (6), 577-590, 2020 | 25 | 2020 |
| Gene therapy in movement disorders: A systematic review of ongoing and completed clinical trials A Merola, N Kobayashi, A Romagnolo, BA Wright, CA Artusi, G Imbalzano, ... Frontiers in neurology 12, 648532, 2021 | 23 | 2021 |
| Non-motor symptoms of Parkinson disease: update on the diagnosis and treatment AD Van Laar, S Jain The neurologist 10 (4), 185, 2004 | 23 | 2004 |
| Data-driven evolution of neurosurgical gene therapy delivery in Parkinson¢s disease RM Richardson, KS Bankiewicz, CW Christine, AD Van Laar, RE Gross, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (11), 1210-1218, 2020 | 19 | 2020 |
| An update on gene therapy approaches for Parkinson¢s disease: restoration of dopaminergic function AD Van Laar, VS Van Laar, W San Sebastian, A Merola, JB Elder, ... Journal of Parkinson's Disease 11 (s2), S173-S182, 2021 | 18 | 2021 |
| LRRK2 activation in idiopathic Parkinson¢s disease. Sci Transl Med 10: eaar5429 R Di Maio, EK Hoffman, EM Rocha, MT Keeney, LH Sanders, ... | 18 | 2018 |
| A central role for LRRK2 in idiopathic Parkinson Disease R Di Maio, EK Hoffman, EM Rocha, MT Keeney, LH Sanders, ... Science translational medicine 10 (451), 2018 | 11 | 2018 |
| Intraputaminal AADC gene therapy for advanced Parkinson's disease: interim results of a phase 1b Trial B Ravina, C Christine, K Bankiewicz, A Van Laar, M Richardson, A Kells, ... Human Gene Therapy 28 (12), A6-A6, 2017 | 5 | 2017 |
